Emideltide FDA vote goes against sleep peptide compounding
FDA advisers voted 7-6 against allowing emideltide to be compounded, citing weak evidence and safety questions around the sleep peptide.
By Frankie Delgado · News Reporter
3 min read
FDA advisers split narrowly against an emideltide FDA vote on Friday, rejecting a bid to let compounding pharmacies legally make the peptide promoted for sleep and opioid-withdrawal uses.
The Food and Drug Administration advisory committee voted 7 against and 6 in favor, with 1 abstention, according to the committee proceedings reported by MarketWatch. The vote marked the panel’s first “no” during a two-day review of seven peptides that have gained traction in wellness circles.
Emideltide is also known as delta sleep-inducing peptide. Todd Durham, an FDA adviser and an executive at the Foundation Fighting Blindness, said he voted against it because of “low-quality evidence around efficacy,” limited information about the bulk drug substance and the existence of approved treatments for some uses.
What is emideltide?
Emideltide is a peptide that has been promoted for insomnia, narcolepsy and opioid withdrawal, according to the FDA advisory discussion. FDA reviewers said studies on its effectiveness existed, but they dated to the 1980s and 1990s and were described by the agency as “inconclusive and at best preliminary.”
The panel’s vote does not decide the issue on its own. FDA leadership must issue the final determination, and while the agency is not required to follow advisory committee recommendations, MarketWatch reported that it traditionally does.
What would peptide compounding mean?
A favorable advisory recommendation would allow compounding pharmacies to legally produce a peptide. It would not mean the FDA had approved the product as safe and effective through the drug-approval process.
The FDA approval process requires clinical-trial data and a formal safety and efficacy review. Critics at the meeting warned that consumers could confuse legal compounding with FDA approval.
Adriane Fugh-Berman, director of a watchdog organization that studies pharmaceutical marketing and a critic of the drug industry, told the committee Thursday that “consumers will interpret reclassification as FDA approval.” She added: “Most of these peptides will harm patients.”
The FDA’s own scientists recommended against reclassifying all seven peptides under review, saying there was not enough information about safety risks, clinical benefits or manufacturing, according to the meeting materials described by MarketWatch.
Which other peptides are under review?
The advisory committee reviewed seven peptides over two days. On Thursday, advisers largely supported allowing pharmacies to compound BPC-157, KPV, TB-500 and MOTS-C, according to MarketWatch.
On Friday, the committee also discussed epitalon and semax. Epitalon has been used for insomnia, and a small Australian biotech once tested it as a possible treatment for retinitis pigmentosa, a group of rare genetic eye diseases, though that research did not succeed, MarketWatch reported.
Semax was discovered and synthesized in Russia, as was epitalon. Of the seven peptides under review, semax is the only one approved in any country, according to MarketWatch: in Russia, it is used for stroke and optic-nerve conditions. Online promotions have pitched it for many neurological conditions, and it is dispensed through nasal drops.
The FDA raised concerns about semax packaging because the agency lacked information about containers compounding pharmacies would use to dispense it, according to the advisory discussion. Votes on epitalon and semax were planned for later Friday.
Peptides have become popular through longevity clinics, fitness influencers, telehealth companies and biohacking circles, MarketWatch reported. Health and Human Services Secretary Robert F. Kennedy Jr. has said he has used peptides.
The debate follows the FDA’s 2023 move to restrict production of 14 compounded peptides. Supporters of reclassification argued at the meeting that patients are already buying peptides from gray-market suppliers, including labs in China, and that U.S. compounding would be safer.
Ricardo Rosselló, the former governor of Puerto Rico, told the committee that the 2023 restrictions “sent patients to markets where those standards don’t exist.”
This story draws on original reporting from MarketWatch.